海外医药行业板块周报：司美格鲁肽长期减重效果获证实，针对肝病的最新临床实验即将开展

Investment Rating - The report maintains a "Buy" recommendation for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights the confirmed long-term weight loss effects of semaglutide, with new clinical trials targeting liver disease set to commence [4]. - The Hang Seng Index rose by 3.11% and the Hang Seng China Enterprises Index increased by 3.21% during the trading week from May 13 to May 17, while the Hang Seng Healthcare Index fell by 0.72% [5]. - Notable stock performances include a 33.90% increase for Viatris, a 24.16% rise for Hong Kong Medical Group, and a 21.30% gain for Cornerstone Pharmaceuticals [6]. Summary by Sections Market Performance - The Hang Seng Index increased by 3.11%, and the Hang Seng China Enterprises Index rose by 3.21% during the specified trading week [5]. - The Hang Seng Healthcare Index experienced a decline of 0.72% [5]. Stock Highlights - The top three performing stocks during the week were Viatris (33.90%), Hong Kong Medical Group (24.16%), and Cornerstone Pharmaceuticals (21.30%) [6]. - The largest decline was seen in Dongyang Sunshine Pharmaceutical, which fell by 14.44% [6]. Clinical Trials and Research - Novo Nordisk is set to initiate a Phase 2 trial to evaluate the effects of semaglutide and two other drugs on patients with alcohol-related liver disease [4]. - The trial will involve 240 adult patients with a history of alcohol consumption, assessing liver function and fibrosis levels [4]. Investment Strategy - The report suggests focusing on stocks with reasonable valuations and catalysts, including ConvaTec (02162.HK), 3SBio (01530.HK), and others [3].